Answers are grounded in this paper and cite their sources.
For lung cancer, the world's number one cancer killer, there has been—unlike the other common cancers (colon, breast, and prostate)—no significant increase in survival or cure rate since the dawn of modern oncology and surgery in the mid-20th century. As such, the exuberance expressed over the recent emergence of molecular-based targeted lung cancer therapies—specifically, EGFR- and ALK-based therapies—showing improved survival, is that much the more satisfying. Yet unfortunately, relatively few patients with lung cancer can benefit from them. Patients with squamous cell carcinoma do not. Even among patients with lung adenocarcinoma, only a minority—and in some groups a small minority—may benefit. EGFR-targeted therapy could potentially benefit almost a third of East Asian patients. But only 7% of white patients with lung cancer have EGFR mutations; African Americans, only 2%.1,2 ALK-based targeted therapy may benefit some patients with lung adenocarcinoma who have the ALK rearrangement, predominantly never-smokers. But smokers, whose lung cancers generally do not possess the ALK rearrangement? Not so much.3,4 For non–East Asian smokers with lung cancer, the exuberance over targeted therapies may not resonate.In a recent issue of the Archives, a multi-institutional study5 demonstrates the potential of another molecular-based lung cancer therapy: folate receptor–targeted therapy. Folate receptor–based therapy could cast a much wider net and encompass many more patients with lung cancer. The study suggests that as many as three-quarters of patients with lung adenocarcinoma, and more than half of patients with squamous cell carcinoma, could potentially benefit from folate receptor–based targeted therapy. And although the study did not investigate ethnicity, other demographic features significant with EGFR- and ALK-based therapies, such as sex and smoking history, were not factors related to increased folate receptor expression in lung cancer tumor cells.And while this study is the first of its kind, and research is preliminary, there are, as the study notes, several folate receptor–targeted therapies currently undergoing evaluation, including an exquisitely termed duel warhead folate conjugate.6 Exuberance reestablished.
No takes yet. Share an insight, caveat, or question.
Timothy Craig Allen (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: